1. Peeters P, Casamayor M, Moïse P et al. An assessment of patient-reported outcome (PRO) instruments used in prostate cancer (PCa) drug trials. 2011 European Multidisciplinary Meeting on Urological Cancers, Barcelona, Spain, 4–6 November.
2. FDA. Guidance for industry—patient-reported outcomes measures: use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (22 April 2014, date last accessed).
3. Toward patient-centered drug development in oncology;Basch;N Engl J Med,2013
4. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012
5. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial;Fizazi;Lancet Oncol,2014